Verma Amanda K, Sun Jie-Lena, Hernandez Adrian, Teerlink John R, Schulte Phillip J, Ezekowitz Justin, Voors Adriaan, Starling Randall, Armstrong Paul, O'Conner Christopher M, Mentz Robert J
Department of Cardiology, Washington University School of Medicine, St. Louis, Missouri.
Department of Statistics, Duke University Medical Center, Durham, North Carolina.
Clin Cardiol. 2018 Jul;41(7):945-952. doi: 10.1002/clc.22981. Epub 2018 Jul 17.
Heart rate and systolic blood pressure (SBP) are prognostic markers in heart failure (HF) with reduced ejection fraction (HFrEF). Their combination in rate pressure product (RPP) as well as their role in heart failure with preserved ejection fraction (HFpEF) remains unclear.
RPP and its components are associated with HFpEF outcomes.
We performed an analysis of Acute Study of Clinical Effectiveness of Nesiritide in Subjects With Decompensated Heart Failure (ASCEND-HF; http://www.clinicaltrials.gov NCT00475852), which studied 7141 patients with acute HF. HFpEF was defined as left ventricular ejection fraction ≥40%. Outcomes were assessed by baseline heart rate, SBP, and RPP, as well as the change of these variables using adjusted Cox models.
After multivariable adjustment, in-hospital change but not baseline heart rate, SBP, and RPP were associated with 30-day mortality/HF hospitalization (hazard ratio [HR]: 1.17 per 5-bpm heart rate, HR: 1.20 per 10-mm Hg SBP, and HR: 1.02 per 100 bpm × mm Hg RPP; all P < 0.05). Baseline SBP was associated with 180-day mortality (HR: 0.88 per 10-mm Hg, P = 0.028). Though change in RPP was associated with 30-day mortality/HF hospitalization, the RPP baseline variable did not provide additional associative information with regard to outcomes when compared with assessment of baseline heart rate and SBP variables alone.
An increase in heart rate and SBP from baseline to discharge was associated with increased 30-day mortality/HF hospitalization in HFpEF patients with acute exacerbation. These findings suggest value in monitoring the trend of vital signs during HFpEF hospitalization.
心率和收缩压(SBP)是射血分数降低的心力衰竭(HFrEF)的预后标志物。它们在心率血压乘积(RPP)中的组合以及在射血分数保留的心力衰竭(HFpEF)中的作用仍不清楚。
RPP及其组成部分与HFpEF的预后相关。
我们对急性失代偿性心力衰竭患者奈西立肽临床疗效的急性研究(ASCEND-HF;http://www.clinicaltrials.gov NCT00475852)进行了分析,该研究纳入了7141例急性心力衰竭患者。HFpEF定义为左心室射血分数≥40%。通过基线心率、SBP和RPP以及使用校正Cox模型对这些变量的变化来评估预后。
经过多变量调整后,住院期间的变化而非基线心率、SBP和RPP与30天死亡率/心力衰竭住院相关(心率每增加5次/分钟的风险比[HR]:1.17,SBP每增加10 mmHg的HR:1.20,RPP每增加100次/分钟×mmHg的HR:1.02;所有P<0.05)。基线SBP与180天死亡率相关(HR:每10 mmHg为0.88,P = 0.028)。尽管RPP的变化与30天死亡率/心力衰竭住院相关,但与单独评估基线心率和SBP变量相比,RPP基线变量在预后方面并未提供额外的关联信息。
在急性加重的HFpEF患者中,从基线到出院时心率和SBP的增加与30天死亡率/心力衰竭住院增加相关。这些发现表明在HFpEF住院期间监测生命体征趋势具有重要意义。